These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Helping map the taxonomical position of the Nontuberculous Mycobacteria (NTM) in cystic fibrosis. Moore JE; Millar BC Int J Mycobacteriol; 2022; 11(3):303-308. PubMed ID: 36260450 [TBL] [Abstract][Full Text] [Related]
24. Adaptive Immune Response to Mauch RM; Jensen PØ; Qvist T; Kolpen M; Moser C; Pressler T; Nolasco da Silva MT; Høiby N; Front Cell Infect Microbiol; 2022; 12():858398. PubMed ID: 35548464 [TBL] [Abstract][Full Text] [Related]
25. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Binder AM; Adjemian J; Olivier KN; Prevots DR Am J Respir Crit Care Med; 2013 Oct; 188(7):807-12. PubMed ID: 23927602 [TBL] [Abstract][Full Text] [Related]
26. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Martiniano SL; Sontag MK; Daley CL; Nick JA; Sagel SD Ann Am Thorac Soc; 2014 Jan; 11(1):36-44. PubMed ID: 24251858 [TBL] [Abstract][Full Text] [Related]
27. Prevalence and factors associated with nontuberculous mycobacteria in non-cystic fibrosis bronchiectasis: a multicenter observational study. Máiz L; Girón R; Olveira C; Vendrell M; Nieto R; Martínez-García MA BMC Infect Dis; 2016 Aug; 16(1):437. PubMed ID: 27549788 [TBL] [Abstract][Full Text] [Related]
28. An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation. Stephenson D; Perry A; Appleby MR; Lee D; Davison J; Johnston A; Jones AL; Nelson A; Bourke SJ; Thomas MF; De Soyza A; Lordan JL; Lumb J; Robb AE; Samuel JR; Walton KE; Perry JD BMC Pulm Med; 2019 Jan; 19(1):19. PubMed ID: 30665395 [TBL] [Abstract][Full Text] [Related]
35. Prevalence and importance of non-tuberculous mycobacteria in adult patients with cystic fibrosis in a hospital in Madrid. Fernández-Caso B; Vázquez R; Alarcón T; Girón R; López-Giménez MR; Domingo D Enferm Infecc Microbiol Clin (Engl Ed); 2020; 38(7):323-326. PubMed ID: 31744623 [TBL] [Abstract][Full Text] [Related]
36. Treating nontuberculous mycobacteria in children with cystic fibrosis: a multicentre retrospective study. Saint GL; Thomas MF; Zainal Abidin N; Langley RJ; Brodlie M; McNamara P; Arch Dis Child; 2022 May; 107(5):479-485. PubMed ID: 34740877 [TBL] [Abstract][Full Text] [Related]
37. Phylogenomics of nontuberculous mycobacteria respiratory infections in people with cystic fibrosis. Bolden N; Mell JC; Logan JB; Planet PJ Paediatr Respir Rev; 2023 Jun; 46():63-70. PubMed ID: 36828670 [TBL] [Abstract][Full Text] [Related]
38. Itaconic acid inhibits nontuberculous mycobacterial growth in pH dependent manner while 4-octyl-itaconic acid enhances THP-1 clearance of nontuberculous mycobacteria in vitro. Breen P; Zimbric M; Caverly LJ PLoS One; 2024; 19(5):e0303516. PubMed ID: 38728330 [TBL] [Abstract][Full Text] [Related]
39. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. Burke A; Smith D; Coulter C; Bell SC; Thomson R; Roberts JA Clin Pharmacokinet; 2021 Sep; 60(9):1081-1102. PubMed ID: 33982266 [TBL] [Abstract][Full Text] [Related]
40. High Prevalence of Nontuberculous Mycobacteria in Cystic Fibrosis Patients in Tropical French Reunion Island. Ho D; Belmonte O; Andre M; Gazaille V; Perisson C; Gachelin E; Allyn J; Payet A; Coolen-Allou N Pediatr Infect Dis J; 2021 Mar; 40(3):e120-e122. PubMed ID: 33427803 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]